Company intelligence / Profile preview

Tamir Biotechnology, Inc.

Monmouth Junction, New Jersey, United Statestamirbio.com ↗

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Ranpirnase demonstrated clear clinical effect in Phase I/II trials targeting genital warts caused by HPV. Over 1,000 patients have been dosed with ranpirnase in cancer/mesothelioma clinical trials, showing strong safety and tolerability profiles. The company's compounds also showed positive antiviral activity against multiple viruses including SARS, Dengue, and outperformed Ganciclovir for Cytomegalovirus in cell culture tests.

Therapeutic areas: OphthalmologyOncologyInfectious Diseases
Modalities: EnzymesRibonucleases (RNases)
Industry: Biotech

Partnerships

National Institute of Allergy and Infectious Diseases (NIAID)

Beyond the preview

Go deeper on Tamir Biotechnology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tamir Biotechnology, Inc..